Webb14 feb. 2024 · Considering the development of fatal ventricular arrhythmias with the ibrutinib-venetoclax combination in the aforementioned study, an ongoing SWOG phase 2 randomized study (NCT04840602), evaluating ibrutinib and rituximab +/− venetoclax among patients with previously untreated WM/lymphoplasmacytic lymphoma has been … Webb18 nov. 2024 · Imbruvica is available as capsules (140 mg) and tablets (140, 280, 420 and 560 mg). For patients with mantle cell lymphoma the dose is 560 mg once a day, and for patients with CLL or Waldenström’s macroglobulinaemia the usual dose of Imbruvica is 420 mg once a day. When used with venetoclax in patients with CLL, Imbruvica is …
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab …
Webb16 sep. 2024 · Herein, we present the final report of a single-center, prospective phase II study evaluating ibrutinib 420 mg once daily in 30 treatment-naive patients with … Webb1 juni 2024 · Among patients with Waldenström’s macroglobulinemia, the use of ibrutinib–rituximab resulted in significantly higher rates of progression-free survival … technogym mywellness key
Bendamustine Plus Rituximab for the Treatment of Waldenström ...
Webb9 apr. 2015 · Ibrutinib is an orally administered, small-molecule inhibitor of BTK that triggers apoptosis of Waldenström’s macroglobulinemia cells with MYD88L265P. … Webb28 okt. 2024 · MYD88 and CXCR4 mutations are common in Waldenström macroglobulinemia (WM). Mutated CXCR4 (CXCR4Mut) impacts BTK-inhibitor response. We conducted a phase 1 trial of the CXCR4-antagonist ulocuplumab with ibrutinib in this first-ever study to target CXCR4Mut in WM. Ibrutinib was initiated at 420 mg/d … Webb10 apr. 2024 · Nemtabrutinib (MK-1026, formerly ARQ-531) is a noncovalent, potent inhibitor of wild-type and ibrutinib-resistant C481S-mutated BTK. This means it could potentially help patients who have progressed after being treated with a covalent BTK inhibitor (e.g., ... 6 with Waldenstrom’s macroglobulinemia, ... technogym olympics